Abstract
The approximate representation of the active site of the type 3 isozyme of the enzyme 17β-hydroxysteroid dehydrogenase (17β-HSD3) has been derived from the consideration of the proposed mechanism for the reduction reaction. Using the transition-state (TS), the mode of action of a number of inhibitors has been rationalised.
Keywords: Type 3, Isozyme, 17β-Hydroxysteroid dehydrogenase, 17β-HSD3, Transition-state, Reduction reaction
Letters in Drug Design & Discovery
Title: The Derivation of a Potential Transition-State for the Reduction Reaction Catalysed by 17β -Hydroxysteroid Dehydrogenase Type 3 (17β -HSD) - An Approximate Representation of its Active Site for Use in Drug Design and Discovery
Volume: 4 Issue: 7
Author(s): Moniola S. Olusanjo and Sabbir Ahmed
Affiliation:
Keywords: Type 3, Isozyme, 17β-Hydroxysteroid dehydrogenase, 17β-HSD3, Transition-state, Reduction reaction
Abstract: The approximate representation of the active site of the type 3 isozyme of the enzyme 17β-hydroxysteroid dehydrogenase (17β-HSD3) has been derived from the consideration of the proposed mechanism for the reduction reaction. Using the transition-state (TS), the mode of action of a number of inhibitors has been rationalised.
Export Options
About this article
Cite this article as:
Olusanjo S. Moniola and Ahmed Sabbir, The Derivation of a Potential Transition-State for the Reduction Reaction Catalysed by 17β -Hydroxysteroid Dehydrogenase Type 3 (17β -HSD) - An Approximate Representation of its Active Site for Use in Drug Design and Discovery, Letters in Drug Design & Discovery 2007; 4 (7) . https://dx.doi.org/10.2174/157018007781788525
DOI https://dx.doi.org/10.2174/157018007781788525 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry From the RB Tumor Suppressor to MCR Peptides
Protein & Peptide Letters Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review
Current Medicinal Chemistry Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives
Mini-Reviews in Medicinal Chemistry Molecular Actions of Polyhalogenated Arylhydrocarbons (PAHs) in Female Reproduction
Current Medicinal Chemistry Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation
Current Topics in Medicinal Chemistry Development and Application of Fourier-Transform Infrared Chemical Imaging of Tumour in Human Tissue
Current Medicinal Chemistry Editorial [Hot topic: Phosphodiesterase-5 Inhibitors and their Use in the Treatment of Urological Conditions (Executive Editor: Perimenis Petros)]
Current Pharmaceutical Design Recent Advances in the Development of Phytoestrogens and Derivatives: An Update of the Promising Perspectives in the Prevention of Postmenopausal Diseases
Mini-Reviews in Medicinal Chemistry Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Small-Animal Molecular Imaging for Preclinical Cancer Research: μPET and μSPECT
Current Radiopharmaceuticals Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry A QSAR Study on a Series of Indolin-2-Ones Acting as Non-Receptor Src Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Single Dose Oral Pharmacokinetic Profile of α-Mangostin in Mice
Current Drug Targets From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Current Pharmaceutical Design A Focus on Heme Oxygenase-1 (HO-1) Inhibitors
Current Medicinal Chemistry